Effects of the SGLT2 Inhibitor Dapagliflozin on Energy Metabolism in Patients With Type 2 Diabetes: A Randomized, Double-Blind Crossover Trial

OBJECTIVE: SGTL2 inhibitors increase urinary glucose excretion and have beneficial effects on cardiovascular and renal outcomes. The underlying mechanism may involve caloric restriction-like metabolic effects due to urinary glucose loss. We investigated the effects of dapagliflozin on 24-h energy me...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Diabetes Care
Päätekijät: Op den Kamp, Yvo J.M., de Ligt, Marlies, Dautzenberg, Bas, Kornips, Esther, Esterline, Russell, Hesselink, Matthijs K.C., Hoeks, Joris, Schrauwen-Hinderling, Vera B., Havekes, Bas, Oscarsson, Jan, Phielix, Esther, Schrauwen, Patrick
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Diabetes Association 2021
Aiheet:
Emerging Therapies: Drugs and Regimens
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC8247491/
https://ncbi.nlm.nih.gov/pubmed/33858855
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2337/dc20-2887
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia